ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

PI3K/mTOR Kinase Inhibitor WXFL10030390

Also written as “WX390”, “WX390 1.1mg + Toripalimab 240mg” and “WXFL10030390”.

Its studies are mostly in Uterine Cervical Neoplasms, led by Shanghai Jiatan Pharmatech.

Drug pagePI3K/mTOR Kinase Inhibitor WXFL10030390: every studyAll 6 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jan 20, 20266 company-led studies, 4 open or runningNext primary completion: Sep 30, 2029 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Shanghai Jiatan Pharmatech64 open or runningphase 3since Jan 20, 2026Oct 21, 2018Sep 30, 2029phase 3 · NCT07392060

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 21, 2018First study: phase 1 study in Hereditary Sensory and Autonomic NeuropathiesFirst studyNCT03730142 · 82 enrolled · China
  2. Oct 30, 20233 phase 2 studiesNCT06124963, NCT06117566, NCT06117540
  3. Nov 3, 2023Phase 2 study in PIK3CA Mutation-Related TumorsNCT06132932 · 38 enrolled · China
  4. Jan 20, 2026Phase 3 study in Cervical Cancer MetastaticPhase 3 reachedNCT07392060 · 440 planned

Ahead

  1. Sep 30, 2029Primary completion: phase 3 study in Cervical Cancer MetastaticNCT07392060

TargetBeta

MTOR →read by rule
“An orally bioavailable, small molecule inhibitor of certain phosphoinositide 3-kinase (PI3K) isoforms and mammalian target of rapamycin kinase (mTOR) in the PI3K/mTOR signaling pathway, ”NCIt, by rule

Other programs on MTOR

ProgramCompanyFurthest phaseStudies
SirolimusPfizerphase 466
gedatolisibrulePfizerphase 39
sapanisertibruleTakedaphase 214

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07392060Cervical Cancer Metastatic3Not yet recruitingSep 30, 2029440
NCT06132932PIK3CA Mutation-Related Tumors · China2CompletedJan 3, 202338
NCT06124963Gastric Type Adenocarcinoma (GAS) With STK11 Mutation · China2RecruitingDec 12, 202520
NCT06117566Solid Tumor · China2RecruitingNov 9, 2025100
NCT06117540Solid Tumor · China2RecruitingJun 12, 202570
NCT03730142Hereditary Sensory and Autonomic Neuropathies · China1CompletedJul 25, 202082

How it is read

Names in the registry

  • “WX390”, 4 entries
  • “WX390 1.1mg + Toripalimab 240mg”, 1 entry
  • “WXFL10030390”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.